Dermatopathology (May 2022)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma

  • Valerie Glutsch,
  • Marion Wobser,
  • Bastian Schilling,
  • Anja Gesierich,
  • Matthias Goebeler,
  • Hermann Kneitz

DOI
https://doi.org/10.3390/dermatopathology9020019
Journal volume & issue
Vol. 9, no. 2
pp. 148 – 157

Abstract

Read online

Background: Rhabdoid melanoma is a rare variant of malignant melanoma with characteristic cytomorphologic features. Due to the potential loss of conventional melanocytic markers, histopathologic diagnosis is often challenging. We hypothesize that immunostaining for PReferentially expressed Antigen in MElanoma (PRAME) might have the potential to uncover the melanocytic origin of these dedifferentiated tumors. Methods: Four cases of rhabdoid primary melanomas were assessed by immunohistochemistry for expression of PRAME and conventional melanocytic markers. Immunohistochemical expression patterns were analyzed in the rhabdoid primaries and, if available, associated metastases. Results: All four cases of rhabdoid primary melanomas showed a strong nuclear positivity for PRAME, while the expression of conventional melanocytic markers S100, MART-1, SOX-10 and HMB-45 was variable between the analyzed cases. Conclusions: In summary, we report four cases of rhabdoid primary melanoma with high to intermediate expression of PRAME despite the partial and variable loss of other melanocytic markers. Hence, PRAME might facilitate the recognition of this highly aggressive entity to avoid misdiagnosis due to histopathologic pitfalls.

Keywords